The invention is directed to osteochondroreticular stem cells and methods of using osteochondroreticular stem cells. In another aspect the invention is directed to a method of treating osteoarthritis or skeletal fractures using osteochondroreticular stem cells.

The present invention relates to methods exogenous nucleic acid molecules, such as RNA, that encode an antibody or antigen-binding fragment of an antibody, and optionally encode a cellular modulation factor and/or a potentiation factor. The cellular modulation factor is a factor that results in increased expression of the antibody and/or antigen-binding fragment. The potentiation factor is a factor that provides desired antibody effector or other properties. The exogenous nucleic acid molecules can be DNA or RNA, as mRNA (including self-replication RNA and non-self-replicating RNA). The invention also relates method for administering the exogenous nucleic acid molecules to a subject to achieve production of the encoded antibody or antigen-binding fragment in the subject to provide, for example, prophylactic or therapeutic passive immunity.

Disclosed is an antitumor vaccine including testicular and fetal tissue-derived components. Cell preparations are prepared from normal tissues harvested directly from animals. Such vaccines may be used in the treatment and prevention of different cancers. For example, a vaccine consisting of glutaraldehyde-treated cells prepared from sheep testis and fetal lung has been found to be effective in inducing antitumor cell-mediated responses, as well as in prolonging the survival of mice with lung cancer.

In some embodiments, compositions and methods relating to isolated artificial antigen presenting cells (aAPCs) are disclosed, including aAPCs comprising a myeloid cell transduced with one or more viral vectors, such as a MOLM-14 or a EM-3 myeloid cell, wherein the myeloid cell endogenously expresses HLA-AB/C, ICOS-L, and CD58, and wherein the one or more viral vectors comprise a nucleic acid encoding CD86 and a nucleic acid encoding 4-1BBL and/or OX40L and transduce the myeloid cell to express CD86 and 4-1BBL and/or OX40L proteins. In some embodiments, methods of expanding tumor infiltrating lymphocytes (TILs) with aAPCs and methods of treating cancers using TILs after expansion with aAPCs are also disclosed.

The invention features methods of producing compositions enriched in Tregs and methods for treating immunological disorders using these compositions. The invention also features methods for producing compositions enriched in lymphocytes and depleted of Tregs and the use of these compositions in the treatment of proliferative disorders.

The present invention relates to an anti-inflammatory, skin-regenerative, whitening, antioxidant, or wound-healing composition containing a culture medium of adipose-derived stem cell-T (ADSC-T) cells as an active ingredient, in which T-antigen is introduced into an adipose-derived stem cell. The culture medium of ADSC-T cells, according to the present invention, has remarkable effects for treating or inhibiting inflammation by alleviating atopic dermatitis, which is an autoimmune disease, and inhibiting NF-κB activities through an increase of an Iκbα expression. Additionally, the culture medium, according to the present invention, exhibits: excellent skin regenerative effects by having effects of enhancing skin collagen elasticity and reducing wounds, in a collagen culture; excellent skin whitening effects by inhibiting tyrosinase activities and melanin production; and excellent anti-oxidation effects by inhibiting DPPH radical activities. Furthermore, the present invention has remarkable wound-healing effects by enhancing cell mobility of fibroblast, and is thus useful for anti-inflammation, skin-regeneration, whitening, anti-oxidation, or healing wounds.

Provided is a pharmaceutical combination comprising an antibody specific for CD19 and a natural killer cell, and a treatment method using the same. Such a pharmaceutical combination is capable of exhibiting synergistic therapeutic effects on a malignant tumor of B-cell origin such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and/or acute lymphoblastic leukemia.

Embodiments of the disclosure include methods and compositions related to treatment and prevention of an excess of cytokines in an individual using fibroblasts or fibroblast-derived microvesicles. In particular embodiments, there are methods and compositions for treating and preventing toxicities in an individual that may be the result of cytokine release syndrome. In specific cases, an individual is treated for cytokine release syndrome with fibroblasts having one or more specific markers.

Methods and compositions for cell therapy using immune modulating peptides comprising a manf family protein, or fragment thereof, as an adjuvant to improve replacement cell viability and integration. The methods and compositions can be used in the treatment of a variety of diseases and disorders, including retinal diseases.

Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to a recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.